<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19476" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cholinesterase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Ravneet</given-names>
          </name>
          <aff>Chicago Medical School Rosalind Franklin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sadiq</surname>
            <given-names>Nazia M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ravneet Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazia Sadiq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19476.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cholinesterase inhibitors function to decrease the breakdown of acetylcholine. They SEe use in the treatment of Alzheimer and dementia symptoms. This activity describes the indications, action, and contraindications for cholinesterase inhibitors in treating dementia disorders and other uses within other specialties. Moreover, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients undergoing treatments requiring cholinesterase inhibitors.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for cholinesterase inhibitor use.</p></list-item><list-item><p>Describe the most common adverse effects associated with cholinesterase inhibitor use.</p></list-item><list-item><p>Summarize the risks associated with initiating cholinesterase use.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst the interprofessional team to improve outcomes for patients receiving cholinesterase inhibitors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19476&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19476">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19476.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cholinesterase inhibitors also have the following names: <italic toggle="yes">acetylcholinesterase (AChE) inhibitors </italic>or <italic toggle="yes">anticholinesterases. </italic>They are a group of drugs that block the normal breakdown of acetylcholine (ACh) into acetate and choline and increase both the&#x000a0;levels and duration of actions of acetylcholine found in the central and peripheral nervous system. The acetylcholinesterase inhibitors have a variety of indications. Most commonly, their use is in treating neurogenerative diseases such as Alzheimer disease, Parkinson disease, and&#x000a0;Lewy body dementia. Different physiological processes in these degenerative disorders destroy cells that produce ACh and reduce cholinergic transmission in different regions of the brain. The cholinesterase inhibitor drugs inhibit&#x000a0;AChE activity and maintain the ACh level by decreasing its breakdown rate.<xref ref-type="bibr" rid="article-19476.r1">[1]</xref></p>
        <p>Also, cholinesterase inhibitors have frequent use in patients with myasthenia gravis. The raised level of acetylcholine in the neuromuscular junction leads&#x000a0;to increased activation of ACh receptors found on post-synaptic membranes resulting in improved&#x000a0;muscle activation, contraction, and strength.</p>
        <p>At the end of surgeries,&#x000a0;cholinesterase inhibitors,&#x000a0;most commonly neostigmine, are administered to reverse the&#x000a0;effects of nondepolarizing muscle agents such as rocuronium.<xref ref-type="bibr" rid="article-19476.r2">[2]</xref><xref ref-type="bibr" rid="article-19476.r3">[3]</xref><xref ref-type="bibr" rid="article-19476.r4">[4]</xref><xref ref-type="bibr" rid="article-19476.r5">[5]</xref><xref ref-type="bibr" rid="article-19476.r6">[6]</xref></p>
        <p>Cholinesterase inhibitors are also necessary to administer when&#x000a0;anticholinergic poisoning is suspected. Symptoms of&#x000a0;anticholinergic poisoning include vasodilation, anhidrosis, mydriasis, delirium, and urinary retention.<xref ref-type="bibr" rid="article-19476.r7">[7]</xref></p>
        <p>Other less common indications of cholinesterase inhibitors include&#x000a0;treating patients diagnosed with certain&#x000a0;psychiatric disorders such as schizophrenia and treatment of glaucoma by relieving aqueous humor pressure.<xref ref-type="bibr" rid="article-19476.r8">[8]</xref></p>
      </sec>
      <sec id="article-19476.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cholinesterase inhibitors function by inhibiting cholinesterase from&#x000a0;hydrolyzing acetylcholine into its components of acetate and choline'; this allows for an increase in the availability and duration of action&#x000a0;of&#x000a0;acetylcholine in&#x000a0;neuromuscular junctions.&#x000a0;The cholinesterase enzyme has&#x000a0;two active sites: an anionic site formed by tryptophan and an esteractic site formed by serine. Cholinesterase inhibitors such as organophosphates inhibit cholinesterase&#x000a0;from cleaving acetylcholine&#x000a0;by interacting with the serine esteractic site. As a result, acetylcholine will continue to&#x000a0;accumulate and activate associated receptors.<xref ref-type="bibr" rid="article-19476.r9">[9]</xref></p>
        <p>Cholinesterase inhibitors classify as reversible, irreversible, or pseudo-reversible. Reversible cholinesterase inhibitors are generally utilized for therapeutic purposes. In contrast, irreversible and pseudo-reversible inhibitors are often used in pesticides and biowarfare (nerve agents).<xref ref-type="bibr" rid="article-19476.r10">[10]</xref><xref ref-type="bibr" rid="article-19476.r11">[11]</xref></p>
      </sec>
      <sec id="article-19476.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cholinesterase inhibitors come in many forms. The administration of many available cholinesterase inhibitors is by&#x000a0;IM, IV,&#x000a0;or oral routes. Different forms can be available for different types of cholinesterase inhibitors. For example, neostigmine has a solution form&#x000a0;used to counteract muscle relaxants at the end of surgeries. For patients with myasthenia gravis, an oral form of neostigmine&#x000a0;is available for treatment. Rivastigmine, used in patients with dementia, has a transdermal patch form that is also frequently used.<xref ref-type="bibr" rid="article-19476.r12">[12]</xref></p>
      </sec>
      <sec id="article-19476.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cholinesterase inhibitors increase the overall amount of acetylcholine available. Thus, symptoms of overstimulation of the parasympathetic nervous system, such as increased hypermotility, hypersecretion, bradycardia, miosis, diarrhea, and hypotension, may be present.</p>
        <p>A major concern when prescribing cholinesterase inhibitors or&#x000a0;exposure to organophosphates is&#x000a0;potentially developing&#x000a0;a cholinergic crisis, also known as <bold>SLUDGE</bold> syndrome.<xref ref-type="bibr" rid="article-19476.r13">[13]</xref></p>
        <p><bold>SLUDGE</bold> is a mnemonic that stands for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>S: </bold>Salivation</p>
          </list-item>
          <list-item>
            <p><bold>L: </bold>Lacrimation</p>
          </list-item>
          <list-item>
            <p><bold>U: </bold>Urination</p>
          </list-item>
          <list-item>
            <p><bold>D: </bold>Diaphoresis</p>
          </list-item>
          <list-item>
            <p><bold>G: </bold>Gastrointestinal upset</p>
          </list-item>
          <list-item>
            <p><bold>E: </bold>Emesis</p>
          </list-item>
        </list>
        <p>Temporary&#x000a0;adverse effects when starting patients&#x000a0;on&#x000a0;cholinesterase inhibitors&#x000a0;include headaches, insomnia, and minor GI issues. Other more concerning effects include&#x000a0;lightheadedness,&#x000a0;weakness, and&#x000a0;weight loss.&#x000a0;Prolonged muscle contraction may also be a presenting feature in patients exposed to cholinesterase inhibitors.<xref ref-type="bibr" rid="article-19476.r14">[14]</xref><xref ref-type="bibr" rid="article-19476.r15">[15]</xref></p>
        <p>Cholinesterase inhibitors such as neostigmine used post-operatively for reversal&#x000a0;of neuromuscular blockade can result in a potential residual neuromuscular block.<xref ref-type="bibr" rid="article-19476.r16">[16]</xref></p>
      </sec>
      <sec id="article-19476.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Due to the ability to increase vagal tone through activation of the parasympathetic nervous system, caution is necessary when administering cholinesterase inhibitors to individuals who have bradycardia or cardiac conduction diseases such as sick sinus syndrome. These individuals are at risk for syncope and falls. Caution is also advised in patients on antihypertensive medications&#x000a0;due to the&#x000a0;possibility of developing severe hypotension.<xref ref-type="bibr" rid="article-19476.r17">[17]</xref></p>
        <p>Moreover, cholinesterase inhibitors are also contraindicated in patients with gastric ulcers due to the increased risk of gastrointestinal bleeding.</p>
        <p>Administration to patients with previous allergies or hypersensitivities to cholinesterase inhibitors and their derivatives is also contraindicated.<xref ref-type="bibr" rid="article-19476.r18">[18]</xref></p>
      </sec>
      <sec id="article-19476.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The therapeutic index for each class of cholinesterase inhibitors varies. Physostigmine has a short half-life with a small therapeutic index and is known to cause adverse effects of nausea, vomiting, stomach cramps, and diarrhea; it is not currently recommended to treat dementia. Donepezil, which can also&#x000a0;be used in Alzheimer disease, is well absorbed and relatively tolerated but produces adverse effects at higher dosages.&#x000a0; The oral capsule form of rivastigmine was known to cause gastrointestinal upset. However, research led to developing a transdermal version, which was proven well-tolerated in many studies.&#x000a0;Donepezil and rivastigmine are FDA approved and associated with fewer adverse effects than older generations of cholinesterase inhibitors. The efficacy and adverse effects of newer generations of cholinesterase inhibitors such as metrifonate are currently under investigation. Blood can be drawn to measure RBC cholinesterase activity if there is difficulty confirming the diagnosis.<xref ref-type="bibr" rid="article-19476.r19">[19]</xref><xref ref-type="bibr" rid="article-19476.r20">[20]</xref>&#x000a0;Galantamine is used for the treatment of cognitive decline in mild to moderate Alzheimer disease.&#x000a0;Galantamine is a potent allosteric potentiating ligand of human nicotinic acetylcholine receptors.&#x000a0;Galantamine also works as a weak competitive and reversible cholinesterase inhibitor in all areas of the body.</p>
      </sec>
      <sec id="article-19476.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The potential toxicity of cholinesterase inhibitors is due to their mechanism of action. The spectrum of toxicity can vary from patient to patient, which is also complicated by the type of cholinesterase inhibitor to which a patient suffers exposure.&#x000a0;SLUDGE syndrome, as described above, is the most recognized form of toxicity for cholinesterase inhibitors. Severe respiratory depression can also present.</p>
        <p>Involuntary movements due to increased acetylcholine at&#x000a0;neuromuscular junctions can also be a sign of toxicity. Muscle fibrillation, fasciculations, and paralysis should raise the suspicion of toxicity.<xref ref-type="bibr" rid="article-19476.r21">[21]</xref></p>
        <p>Miosis is a common sign of cholinergic toxicity. The excess acetylcholine causes the contraction of the sphincter pupillae muscle that encompasses the iris. Miosis is&#x000a0;considered one of the most sensitive signs of exposure to aerosol cholinesterase inhibitors (organophosphates, pesticides).<xref ref-type="bibr" rid="article-19476.r22">[22]</xref></p>
        <p>First-line treatments for suspected cholinesterase inhibitor toxicity include atropine, 2-PAM (pralidoxime), and diazepam. Atropine occupies muscarinic receptor sites, therefore reducing the binding of acetylcholine. However, it does not counteract nicotinic effects such as muscle fasciculations and weakness, so ventilation may still be necessary.<xref ref-type="bibr" rid="article-19476.r23">[23]</xref>&#x000a0;</p>
        <p>2-PAM functions by reversing the binding of cholinesterase inhibitors to acetylcholinesterase. When administered together, 2-PAM and atropine have a synergistic effect.<xref ref-type="bibr" rid="article-19476.r24">[24]</xref></p>
        <p>Seizures due to cholinesterase inhibitor toxicity are more apparent in pediatric patients and adults exposed to nerve agents, hence requiring immediate management with diazepam.</p>
      </sec>
      <sec id="article-19476.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team is required to manage patients who are being treated with cholinesterase inhibitors successfully. Since most patients with cholinesterase inhibitor toxicity first present to the emergency department, the triage nurse must be familiar with the symptoms; these patients need immediate admission to a monitored unit. To improve outcomes, a team of nurses, laboratory technicians, pharmacists, physicians, and other healthcare professionals are essential to optimize care, especially when considering cholinesterase inhibitor toxicity. Patients admitted under these circumstances need close monitoring by the nurses and other clinicians. Ordering labs, understanding patient symptoms, and being vigilant to the next treatment steps are necessary to manage patients who are experiencing toxicity due to cholinesterase inhibitor use. Pharmacists should be consulted about the use of atropine, pralidoxime, and benzodiazepines if cholinesterase inhibitor-toxicity is suspected. A toxicologist consult should also occur, with an intensivist, to further manage a patient as many of these cases require further interventional management during the hospital course. Only through this type of interprofessional coordination can patients experiencing cholinergic toxicity achieve optimal clinical results. [Level 5]</p>
        <p>Apart from toxicity, cholinesterase inhibitor therapy for conditions such as dementia and Alzheimer disease also requires interprofessional collaboration. Given the status of patients with these conditions being unable to participate in their treatment, the dosing clinician, the administering nursing staff, and the pharmacist must have input and cross-communication to ensure proper agent selection, dosing, administration, and monitoring of side effects. Again, interprofessional collaboration is crucial to patient outcomes. [Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Patients who are managed immediately after poisoning have good outcomes, but delays in treatment can lead to adverse outcomes.</p>
      </sec>
      <sec id="article-19476.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19476&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19476">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19476/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19476">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19476.s11">
        <title>References</title>
        <ref id="article-19476.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Krsti&#x00107;</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Lazarevi&#x00107;-Pa&#x00161;ti</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Bond&#x0017e;i&#x00107;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vasi&#x00107;</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitors: pharmacology and toxicology.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-35</page-range>
            <pub-id pub-id-type="pmid">24179466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>NLS</given-names>
              </name>
              <name>
                <surname>Wat</surname>
                <given-names>KHY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>JHY</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>CCW</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kng</surname>
                <given-names>CPL</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>LCW</given-names>
              </name>
            </person-group>
            <article-title>Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.</article-title>
            <source>Am J Alzheimers Dis Other Demen</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>302</fpage>
            <page-range>302-307</page-range>
            <pub-id pub-id-type="pmid">31064198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diffuse Lewy body disease.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Apr</month>
            <day>15</day>
            <volume>399</volume>
            <fpage>144</fpage>
            <page-range>144-150</page-range>
            <pub-id pub-id-type="pmid">30807982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.</article-title>
            <source>Exp Ther Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>1611</fpage>
            <page-range>1611-1624</page-range>
            <pub-id pub-id-type="pmid">30783428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Utsumi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maeno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aizawa</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2018</year>
            <season>Sep/Oct</season>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>164</fpage>
            <page-range>164-170</page-range>
            <pub-id pub-id-type="pmid">30130259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shoja Shafti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azizi Khoei</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>308</fpage>
            <page-range>308-316</page-range>
            <pub-id pub-id-type="pmid">27721970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Anam</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Barua</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Donepezil: an unusual therapy for acute diphenhydramine overdose.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30898954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostergaard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Engbaek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viby-Mogensen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions and interactions of the neuromuscular blocking drugs.</article-title>
            <source>Med Toxicol Adverse Drug Exp</source>
            <year>1989</year>
            <season>Sep-Oct</season>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>351</fpage>
            <page-range>351-68</page-range>
            <pub-id pub-id-type="pmid">2682131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bagetta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cagide</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amorim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garrido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Remi&#x000e3;o</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Uriarte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Alcaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ortuso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Borges</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents.</article-title>
            <source>Eur J Med Chem</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>174</volume>
            <fpage>116</fpage>
            <page-range>116-129</page-range>
            <pub-id pub-id-type="pmid">31029943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Fabricating an Acetylcholinesterase Modulated UCNPs-Cu<sup>2+</sup> Fluorescence Biosensor for Ultrasensitive Detection of Organophosphorus Pesticides-Diazinon in Food.</article-title>
            <source>J Agric Food Chem</source>
            <year>2019</year>
            <month>Apr</month>
            <day>10</day>
            <volume>67</volume>
            <issue>14</issue>
            <fpage>4071</fpage>
            <page-range>4071-4079</page-range>
            <pub-id pub-id-type="pmid">30888170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajgar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kassa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kucera</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Musilek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kuca</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Some Possibilities to Study New Prophylactics against Nerve Agents.</article-title>
            <source>Mini Rev Med Chem</source>
            <year>2019</year>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>970</fpage>
            <page-range>970-979</page-range>
            <pub-id pub-id-type="pmid">30827238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>Skinfold thickness for rivastigmine patch application in Alzheimer's disease.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>236</volume>
            <issue>4</issue>
            <fpage>1255</fpage>
            <page-range>1255-1260</page-range>
            <pub-id pub-id-type="pmid">30645680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohbe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fushimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cholinergic Crisis Caused by Cholinesterase Inhibitors: a Retrospective Nationwide Database Study.</article-title>
            <source>J Med Toxicol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-241</page-range>
            <pub-id pub-id-type="pmid">29907949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Long-Lasting Enhancing Effect of Distigmine on Acetylcholine-Induced Contraction of Guinea Pig Detrusor Smooth Muscle Correlates with Its Anticholinesterase Activity.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2017</year>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>1092</fpage>
            <page-range>1092-1100</page-range>
            <pub-id pub-id-type="pmid">28674252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inglis</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.</article-title>
            <source>Int J Clin Pract Suppl</source>
            <year>2002</year>
            <month>Jun</month>
            <issue>127</issue>
            <fpage>45</fpage>
            <page-range>45-63</page-range>
            <pub-id pub-id-type="pmid">12139367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>2397</fpage>
            <page-range>2397-2406</page-range>
            <pub-id pub-id-type="pmid">30573962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Normand</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.</article-title>
            <source>Arch Intern Med</source>
            <year>2009</year>
            <month>May</month>
            <day>11</day>
            <volume>169</volume>
            <issue>9</issue>
            <fpage>867</fpage>
            <page-range>867-73</page-range>
            <pub-id pub-id-type="pmid">19433698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonner</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Peskind</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic treatments of dementia.</article-title>
            <source>Med Clin North Am</source>
            <year>2002</year>
            <month>May</month>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>657</fpage>
            <page-range>657-74</page-range>
            <pub-id pub-id-type="pmid">12171061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sabbagh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New acetylcholinesterase inhibitors for Alzheimer's disease.</article-title>
            <source>Int J Alzheimers Dis</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>728983</fpage>
            <pub-id pub-id-type="pmid">22216416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belle</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Kumbarakeri Rajashekhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jogi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prabhu</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Correlation of Red Blood Cell Acetylcholinesterase Enzyme Activity with Various RBC Indices.</article-title>
            <source>Indian J Clin Biochem</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-449</page-range>
            <pub-id pub-id-type="pmid">30319191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pope</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Brimijoin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cholinesterases and the fine line between poison and remedy.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>153</volume>
            <fpage>205</fpage>
            <page-range>205-216</page-range>
            <pub-id pub-id-type="pmid">29409903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattio</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Giacobini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effects of DFP on iridic metabolism and release of acetylcholine and on pupillary function in the rat.</article-title>
            <source>Neuropharmacology</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>1207</fpage>
            <page-range>1207-14</page-range>
            <pub-id pub-id-type="pmid">6521855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wig</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Is atropine alone sufficient in acute severe organophosphorus poisoning?: experience of a North West Indian Hospital.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>628</fpage>
            <page-range>628-30</page-range>
            <pub-id pub-id-type="pmid">8688989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19476.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burillo-Putze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Duenas-Laita</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Late administration of pralidoxime in organophosphate (fenitrothion) poisoning.</article-title>
            <source>Am J Emerg Med</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-8</page-range>
            <pub-id pub-id-type="pmid">15258887</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
